Trial Profile
A Phase I, Single Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Tolerability of C1 Inhibitor (CINRYZE) as a Donor Pre-treatment Strategy in Brain Dead Donors Who Meet a Kidney Donor Risk Index (KDRI) Above 60%
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Complement C1 inhibitor protein (Primary) ; Heparin
- Indications Delayed graft function
- Focus Therapeutic Use
- 21 Oct 2020 Planned initiation date changed from 1 Oct 2020 to 1 Dec 2020.
- 01 Sep 2020 Planned initiation date changed from 1 Sep 2020 to 1 Oct 2020.
- 04 Jun 2020 Planned initiation date changed from 1 Jun 2020 to 1 Sep 2020.